Novo Nordisk Launches Novo Rebrand and New Corporate Culture
BAGSVAERD, Denmark — September 14, 2026 Novo Nordisk A/S announced the launch of a new corporate brand centred on...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BAGSVAERD, Denmark — September 14, 2026 Novo Nordisk A/S announced the launch of a new corporate brand centred on...
Orlando, Florida, USA, August, 10, 2026 Independent research from the Medical University of South Carolina (MUSC) Telehealth Center of...
NEW YORK, July 7, 2026 The American Parkinson Disease Association (APDA) has announced the launch of “Bridging Mental Health...
MIAMI, June 20, 2026 INTCO Medical, a leading global manufacturer of disposable gloves and medical devices, highlighted its expanding...
TOKYO, Japan and FRANKFURT, Germany, June 19, 2026 Teijin Pharma Limited and Merz Therapeutics GmbH have announced that Japan’s...
NAIROBI, Kenya / KAMPALA, Uganda, June 19, 2026 African health leaders, government officials, clinicians, patient advocates, and international partners...
AMSTERDAM, Netherlands and YORK, Pa., June 4, 2026 Royal Philips and WellSpan Health have announced a landmark seven-year strategic...
BREMEN, Germany, May 5, 2026 Smith+Nephew, the global medical technology company specializing in advanced wound management and surgical innovation,...
CALGARY, Alberta — December 4, 2025 — Hemostemix Inc., a leader in autologous stem-cell therapeutics, has appointed Shaune Harding,...
THOUSAND OAKS, Calif., Oct. 1, 2025 — Amgen announced that its landmark VESALIUS-CV Phase 3 trial met primary endpoints...
